Cardiac Troponin Levels in Neonates Who Require ECMO for Noncardiac Indications Are Elevated in Nonsurvivors

Astoria, Mark T.; Karam, Simon; Moores, Russell R.; Rozycki, Henry J.

doi:10.1055/s-0034-1543983

Cited by 8 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings revealed that early absolute values of cTnT and NT-proBNP in the death group were significantly higher than those in survivors, with a notably lower rate of decline. ECMO technology facilitates circulation and gas exchange, providing time for the recovery of compromised respiratory and circulatory systems [ 14 , 15 ]. While many studies have explored cTnT and NT-proBNP in ECMO treatment of fulminant myocarditis, research focusing on neonates under 4 kg and receiving ECMO within their first week is limited.…”

Section: Discussionmentioning

confidence: 99%

Early changes in cardiac troponin T and NT-proBNP levels in neonates receiving ECMO support: a single-center experience

Xie,

Liu,

Zeng

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Objective This study aimed to examine the changes in absolute value and decline rate of early serum cardiac troponin T (cTnT) and N-terminal pro b-type natriuretic peptide (NT-proBNP) in neonates who received veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO) support therapy within the first week of life. Methods We retrospectively collected clinical data and laboratory test results of 18 neonates who underwent V-A ECMO support within one week of birth, from July 2021 to June 2023, using the electronic medical record system. These patients were categorized into survival and death groups. Comparative analyses of the absolute values and decline rates of cTnT and NT-proBNP were made between the groups at baseline, and at 24, 48, and 72 h post-ECMO initiation. Results Out of the 18 neonates, 12 survived (survival rate: 66.7%), while 6 succumbed. The survival group exhibited significantly lower absolute values of cTnT and NT-proBNP than the death group, and their decline rates were significantly higher. Notably, all neonates without an early decline in cTnT and NT-proBNP levels were in the death group. Conclusion The early changes in the absolute value and decline rate of serum cTnT and NT-proBNP in neonates undergoing V-A ECMO may serve as predictors of their prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Early changes in cardiac troponin T and NT-proBNP levels in neonates receiving ECMO support: a single-center experience

Xie,

Liu,

Zeng

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

Postoperative Troponin Levels in Children Undergoing Open Heart Surgery With and Without Coronary Intervention

Gikandi,

Gauvreau,

Kohlsaat

et al. 2023

Pediatr Cardiol

View full text Add to dashboard Cite

High-Sensitivity Troponin T and N-Terminal Pro-Brain Natriuretic Peptide in Prediction of Outcome in Congenital Diaphragmatic Hernia: Results from a Multicenter, Randomized Controlled Trial

Snoek

Kraemer

Kate

et al. 2016

The Journal of Pediatrics

View full text Add to dashboard Cite

Cardiac Troponin Levels in Neonates Who Require ECMO for Noncardiac Indications Are Elevated in Nonsurvivors

Abstract: cTnI is an independent biomarker for poor outcome in neonates who receive ECMO therapy for noncardiac generations.

Cited by 8 publications

References 17 publications

Early changes in cardiac troponin T and NT-proBNP levels in neonates receiving ECMO support: a single-center experience

Early changes in cardiac troponin T and NT-proBNP levels in neonates receiving ECMO support: a single-center experience

Postoperative Troponin Levels in Children Undergoing Open Heart Surgery With and Without Coronary Intervention

High-Sensitivity Troponin T and N-Terminal Pro-Brain Natriuretic Peptide in Prediction of Outcome in Congenital Diaphragmatic Hernia: Results from a Multicenter, Randomized Controlled Trial

Contact Info

Product

Resources

About